Cargando…
Low-Dose Anti-HIV Drug Efavirenz Mitigates Retinal Vascular Lesions in a Mouse Model of Alzheimer’s Disease
A small dose of the anti-HIV drug efavirenz (EFV) was previously discovered to activate CYP46A1, a cholesterol-eliminating enzyme in the brain, and mitigate some of the manifestation of Alzheimer’s disease in 5XFAD mice. Herein, we investigated the retina of these animals, which were found to have g...
Autores principales: | El-Darzi, Nicole, Mast, Natalia, Buchner, David A., Saadane, Aicha, Dailey, Brian, Trichonas, Georgios, Pikuleva, Irina A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198296/ https://www.ncbi.nlm.nih.gov/pubmed/35721135 http://dx.doi.org/10.3389/fphar.2022.902254 |
Ejemplares similares
-
N,N-Dimethyl-3β-hydroxycholenamide Reduces Retinal Cholesterol via Partial Inhibition of Retinal Cholesterol Biosynthesis Rather Than its Liver X Receptor Transcriptional Activity
por: El-Darzi, Nicole, et al.
Publicado: (2018) -
The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(−/−) mice
por: El-Darzi, Nicole, et al.
Publicado: (2023) -
The Interplay between Retinal Pathways of Cholesterol Output and Its Effects on Mouse Retina
por: Petrov, Alexey M., et al.
Publicado: (2019) -
CYP46A1-dependent and independent effects of efavirenz treatment
por: Mast, Natalia, et al.
Publicado: (2020) -
Characterizations of Hamster Retina as a Model for Studies of Retinal Cholesterol Homeostasis
por: El-Darzi, Nicole, et al.
Publicado: (2021)